North American Journal of Medical Sciences

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 8  |  Issue : 7  |  Page : 297--306

Thimerosal-containing hepatitis B vaccine exposure is highly associated with childhood obesity: A case-control study using the vaccine safety datalink


David A Geier1, Janet K Kern2, Kristin G Homme3, Lisa K Sykes5, Mark R Geier1 
1 Department of Research, Institute of Chronic Illnesses Inc.; Department of Research, CoMeD, Inc., Silver Spring, MD, USA
2 Department of Research, Institute of Chronic Illnesses Inc.; Department of Research, CoMeD, Inc., Silver Spring, MD; CONEM US Autism Research Group, Allen, TX, USA
3 International Academy of Oral Medicine and Toxicology, Champions Gate, FL, USA

Correspondence Address:
Janet K Kern
Institute of Chronic Illnesses, Inc., 14 Redgate Court, Silver Spring, Maryland -20905
USA

Background: Obesity among children and adolescents in the United States has tripled since 1980, and has become a major public health concern. Aims: The purpose of this study was to evaluate the potential relationship between exposure to organic mercury from Thimerosal-containing hepatitis B vaccines and the children«SQ»s subsequent risk of an obesity diagnosis. Materials and Methods: A hypothesis-testing, case-control study was undertaken to evaluate exposure to organic mercury from Thimerosal-containing hepatitis B vaccines, which were administered at specific intervals in the first 6 months of life, among cases diagnosed with childhood obesity and controls by examining automated medical records for children born from 1991 to 2000 who were continuously enrolled in the Vaccine Safety Datalink database. Results: This study found highly significant associations as follows. Cases diagnosed with obesity were significantly (P < 0.00001) more likely to have received greater exposure to organic mercury from Thimerosal-containing hepatitis B vaccines administered within the first month of life (odds ratio (OR) =1.511), first 2 months of life (OR = 1.486), and first 6 months of life (OR = 3.795) than the controls. Similar outcomes were observed when the overall data were separated by gender. In a dose-response manner, cases diagnosed with obesity were significantly more likely than controls to have received greater exposure to organic mercury from Thimerosal-containing hepatitis B vaccines, which were administered within the first 6 months of life (OR = 1.0375 per μg of mercury, P < 0.00001). Conclusions: In a dose-response manner, the present study associates an increased organic mercury exposure from Thimerosal-containing hepatitis B vaccines with an increased risk of obesity diagnosis, and suggests that Thimerosal is an obesogen. The results are biologically plausible and future studies are needed to examine this phenomenon.


How to cite this article:
Geier DA, Kern JK, Homme KG, Sykes LK, Geier MR. Thimerosal-containing hepatitis B vaccine exposure is highly associated with childhood obesity: A case-control study using the vaccine safety datalink.North Am J Med Sci 2016;8:297-306


How to cite this URL:
Geier DA, Kern JK, Homme KG, Sykes LK, Geier MR. Thimerosal-containing hepatitis B vaccine exposure is highly associated with childhood obesity: A case-control study using the vaccine safety datalink. North Am J Med Sci [serial online] 2016 [cited 2021 Dec 8 ];8:297-306
Available from: https://www.najms.org/article.asp?issn=1947-2714;year=2016;volume=8;issue=7;spage=297;epage=306;aulast=Geier;type=0